Avalo Therapeutics
AVTX
4 hedge funds and large institutions have $3.35M invested in Avalo Therapeutics in 2015 Q4 according to their latest regulatory filings, with 4 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MAM
MPM Asset Management
Boston,
Massachusetts
|
+$2.27M |
| 2 |
NMC
NEA Management Company
Timonium,
Maryland
|
+$2.27M |
| 3 |
BCCM
Blue Clay Capital Management
Minneapolis,
Minnesota
|
+$164K |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$21.9K |
Top Sellers
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
MAM
1
MPM Asset Management
Boston,
Massachusetts
| $2M | +$2.27M | +207 | New |
|
|
NMC
2
NEA Management Company
Timonium,
Maryland
| $1.2M | +$2.27M | +207 | New |
|
|
BCCM
3
Blue Clay Capital Management
Minneapolis,
Minnesota
| $140K | +$164K | +15 | New |
|
|
4
Citadel Advisors
Miami,
Florida
| $19K | +$21.9K | +2 | New |
|
|
TRCT
5
Tower Research Capital (TRC)
New York
| $3K | – | – | – |
|
6
UBS Group
Zurich,
Switzerland
| $1K | – | – | – |
|
AVTX Hedge Fund Activity: Q4 2015 in Review
4 of the 3,812 institutional investors tracked by Wall St. Rank reported a position in Avalo Therapeutics (AVTX) for Q4 2015, worth a combined $3.35M.
Buyers outnumbered sellers: 4 funds opened new AVTX positions and 0 closed out — a net gain of 4 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was MPM Asset Management, opening a new position worth an estimated $2.27M.
- 4 institutional investors held Avalo Therapeutics (AVTX) as of Q4 2015, up from 0 in Q3 2015.
- Funds reported $3.35M of Avalo Therapeutics stock for Q4 2015.
- 4 funds opened new Avalo Therapeutics positions in Q4 2015 and 0 closed out, a net change of +4 holders.
- The largest Avalo Therapeutics buyer in Q4 2015 was MPM Asset Management, an estimated $2.27M added.
Based on aggregated 13F filings for Q4 2015.